Vitals Knowledge Vault

Ivermectin — Colon Cancer

8 min read

Ivermectin — Colon Cancer

Topic: Ivermectin and colorectal cancer (CRC) Evidence status: Entirely preclinical. Zero human clinical trials registered or published for ivermectin in colorectal cancer. Critical fact: The dose required to match in vitro anticancer activity in humans is approximately 2–20× the maximum approved antiparasitic dose. No human study has reached anticancer-active plasma concentrations.

Zero Human Trials — The Foundational Fact

No published or registered clinical trial tests ivermectin in colorectal cancer patients (PubMed, PMC, ClinicalTrials.gov, April 2026).

  • Phase I: 0 registered or published for CRC
  • Phase II: 0 registered or published for CRC
  • Phase III: 0 registered or published for CRC
  • Case reports: 0 published
  • Systematic reviews: 0 specifically for ivermectin + CRC (general cancer reviews note the absence)

The only active oncology trial for ivermectin is NCT05318469 (ivermectin + balstilimab in triple-negative breast cancer) — not colon cancer.

Source: PMID:40715995 (Patel et al., Curr Oncol Rep. 2025); systematic ClinicalTrials.gov search

The ~200-Fold Dose Gap

This is the single most important fact for evaluating the ivermectin–CRC claim.

What Kills CRC Cells in a Dish

CRC Cell LineIvermectin IC50
DLD1~0.8 μM (800 nM)
Ls174T~1.0 μM (1,000 nM)
CC36~1.7 μM (1,700 nM)
CC14~2.3 μM (2,300 nM)
Median across cancer types~5 μM (5,000 nM)

What Humans Can Safely Achieve

Human DoseFree Plasma Concentration
Standard antiparasitic (200 μg/kg)~4.2 nM free
Highest safe tested (~2 mg/kg)~20–25 nM free
Disconnect from lowest CRC IC50~190× below
Disconnect from median IC50~200–250× below

Human Equivalent Dose (HED) Translation

Preclinical CRC studies use 5–50 mg/kg/day in mice (IP or oral). HED conversion (×12.3):

Rodent DoseHED (70 kg adult)
5 mg/kg/day~28 mg/dose
10 mg/kg/day~56 mg/dose
50 mg/kg/day~280 mg/dose

Standard approved dose: ~14 mg. The lowest anticancer-active rodent HED (~28 mg) is 2× the maximum approved single dose. Mid-range (~56 mg) is 4× the approved maximum. High range (~280 mg) is 20× the approved maximum.

Bottom line: Even if all the mechanisms observed in cell culture are real, achieving them in a human would require doses with no established safety profile.

Preclinical Mechanisms in CRC Models

The following mechanisms have been demonstrated in CRC-specific or CRC-inclusive models. Evidence grades are for preclinical strength; all are Grade C for human translation.

1. P-gp / Drug Resistance Reversal (HIGH evidence; CRC primary model)

  • Study: Jiang et al., J Exp Clin Cancer Res. 2019 (PMID:31215501)
  • Model: HCT-8 and HCT-116 CRC cells; nude mouse xenografts
  • Finding: Ivermectin directly binds EGFR extracellular domain (Octet RED96 confirmed); suppresses ERK/Akt/NF-κB cascade → reduces MDR1/P-gp transcription
  • In vivo result: 2 mg/kg ivermectin + 0.2 mg/kg vincristine reduced resistant xenograft tumor volume from 2,794 mm³ to 1,655 mm³
  • Evidence grade: HIGH for mechanism; Grade C for human translation

2. WNT-TCF Pathway Inhibition (HIGH evidence; CRC cell lines + xenograft)

  • Study: Juarez et al., Am J Cancer Res. 2018 (PMC5835698)
  • Model: DLD1, Ls174T, CC14, CC36; DLD1 and HT29 xenografts
  • Finding: 0.1–5 μM ivermectin inhibits WNT-TCF transcriptional activity; IC50 0.8–2.3 μM; AXIN2/LGR5/ASCL2 (CRC stem cell markers) suppressed; cyclin D1 suppressed; IFN-related genes induced
  • In vivo: 10 mg/kg i.p. inhibited DLD1 and HT29 tumor growth
  • Spheroid reduction: up to 73% (CRC spheroids are WNT-dependent)
  • Evidence grade: HIGH for mechanism; Grade C for human translation

3. PAK1/mTOR Pathway Suppression (HIGH evidence; CRC cells ivermectin-sensitive)

  • Study: Liu et al., Drug Des Devel Ther. 2020 (PMC6982461)
  • Model: Multiple cancer cell lines including DLD1, Ls174T
  • Finding: PAK1 degradation → decreased p-Akt(S473), p-mTOR(S2481), p-p70S6K, p-4EBP1 → cytostatic autophagy
  • Evidence grade: HIGH for mechanism; Grade C for CRC-specific efficacy

4. Mitochondrial Apoptosis / ROS Induction (HIGH evidence; CRC cells included)

  • Study: Liu et al., Drug Des Devel Ther. 2020; Juarez et al., 2018
  • Finding: Complex I inhibition → ↓OCR, ↓mitochondrial membrane potential, ↑ROS → cytochrome c release → caspase-9 → caspase-3 → PARP cleavage; DLD1 and Ls174T show activated caspase-3; ROS scavengers abrogate cytotoxicity
  • Evidence grade: HIGH for mechanism; Grade C for human translation

5. Cancer Stem Cell Inhibition (HIGH evidence; CRC spheroid data)

  • Study: Juarez et al., 2018
  • Finding: CD44+/CD24- CSC population preferentially killed; Nanog/Oct4/Sox2 reduced 50–80% at 0.5 μM; clonogenic tumorsphere growth reduced 90–100%; CRC spheroid formation reduced up to 73%
  • Evidence grade: HIGH for CRC spheroid mechanism; Grade C for human translation

6. Immunogenic Cell Death (MODERATE evidence; CT26 murine CRC cells)

  • Study: Liu et al., 2020
  • Finding: P2X4/P2X7 potentiation → ATP/HMGB1 release → caspase-1 pyroptosis; CT26 (murine colon carcinoma) cells show calreticulin exposure and HMGB1 release
  • Evidence grade: MODERATE (CRC cells included); Grade C for human translation

7. Anti-Angiogenesis (MODERATE evidence; glioblastoma/HBMEC; no CRC xenograft)

  • Finding: 10 μM ivermectin abolishes HBMEC tube formation; 40 mg/kg i.p. inhibits glioblastoma tumor angiogenesis; no direct CRC tumor vascularization data
  • Evidence grade: MODERATE (endothelial); Grade C for CRC

8. YAP1/Hippo (LOW evidence; gastric cancer primary; CRC not studied)

  • Finding: Nuclear YAP1 reduction in gastric cancer xenografts; YAP1 nuclear accumulation is a poor prognostic marker in CRC but direct ivermectin-YAP1 data for CRC absent
  • Evidence grade: LOW for CRC

FLT3 Targeting Claim — Mechanistically Invalid for CRC

A specific claim circulating in social media: “Ivermectin targets FLT3 to kill colon cancer stem cells.”

Verdict: MECHANISTICALLY INVALID for colorectal cancer.

  • FLT3 (Fms-like Tyrosine Kinase 3) is predominantly expressed in hematopoietic stem cells; clinically validated target in AML, not CRC
  • TCGA/GTEx: FLT3 mRNA is ~100–1,000× higher in bone marrow/AML than colon tissue
  • FLT3 inhibitors (midostaurin, gilteritinib) are FDA-approved for AML with FLT3-ITD mutations — a biology entirely distinct from CRC
  • Ivermectin’s weak off-target FLT3 inhibition at supraphysiological concentrations (5–10 μM) does not constitute a therapeutic target
  • Regorafenib (multi-kinase inhibitor including FLT3) shows limited efficacy in FLT3-amplified mCRC — even direct FLT3 targeting has not proven effective in CRC

This is a textbook example of mechanistic overreach: taking a valid molecular target from one cancer type (AML) and inappropriately applying it to another (CRC).

DOH+ Protocol — Zero Evidence

The “DOH+” protocol for colon cancer does not appear in any peer-reviewed oncology literature, ClinicalTrials.gov, NCCN guidelines, or FDA databases.

  • No published dosing rationale
  • No clinical trial registration
  • Promoted exclusively through alternative medicine channels and social media
  • Often bundled with other unproven therapies (fenbendazole, DCA, high-dose vitamin C)
  • Practitioners typically lack American Board of Medical Specialties oncology certification
  • Financial extraction from vulnerable cancer patients documented

Red flags for Vitals coaches: Any member encountering “DOH+ protocol” recommendations should be directed to evidence-based CRC treatment. The absence of peer-reviewed evidence is itself the most important signal.

Comparison to Standard of Care

StageStandard of CareIvermectin Evidence
Stage ISurgery alone (>90% 5-year OS)None
Stage IISurgery ± adjuvant capecitabine/5-FU/FOLFOX (high-risk)None
Stage IIISurgery + adjuvant FOLFOX/CAPOX (30–40% recurrence reduction)None
Stage IV (MSS/pMMR)Chemo + anti-VEGF or anti-EGFR; FOLFOXIRI; targeted therapyNone
Stage IV (MSI-H/dMMR)Pembrolizumab or nivolumab ± ipilimumab (KEYNOTE-177: PFS 16.5 vs 8.2 months)None
Emerging (2024–2026)Neoadjuvant ICI (NICHE-2: 95% pathologic response); KRAS G12C + anti-EGFR; HER2+ tucatinib + trastuzumab; ctDNA-guided adjuvantNone

Ivermectin does not appear in any NCCN guideline, ESMO guideline, ASCO guideline, or emerging therapy pathway for colorectal cancer.

Skeptic Summary

What Is True

  • Ivermectin kills CRC cell lines at μM concentrations in vitro
  • Multiple mechanistically plausible anticancer targets are biophysically validated
  • WNT pathway inhibition is particularly relevant (~80% of CRC has APC mutation)
  • P-gp reversal via direct EGFR binding is the most CRC-relevant and best-validated mechanism
  • CSC inhibition in CRC spheroid models is robust

What Is Not True

  • Ivermectin “cures” colon cancer (zero human evidence; preclinical only)
  • FLT3 is a valid target for ivermectin in CRC (FLT3 is not meaningfully expressed in CRC)
  • DOH+ protocol is a legitimate cancer treatment (zero peer-reviewed evidence)
  • Social media testimonials constitute evidence (survivorship bias; no pathological confirmation)
  • “Safe at approved doses” means safe at anticancer doses (10–100× higher)
  • In vitro IC50 concentrations are achievable at safe human doses (~200-fold gap)

Political Contamination

Ivermectin’s COVID-19 controversy has severely contaminated its scientific discourse. Researchers who studied ivermectin for COVID were publicly labeled as grifters, damaging their credibility and making oncology funding harder. The pro-ivermectin community now promotes it for other conditions, conflating political identity with medical evidence. Mainstream oncology journals may avoid ivermectin research to sidestep association. The result is a polarized evidence landscape where objective evaluation is extraordinarily difficult.

Vitals Coaching Implications

For Members with a CRC Diagnosis or High Risk

  1. Do not recommend ivermectin as a cancer treatment. The evidence is entirely preclinical and the dose gap is categorical.
  2. Prevent treatment delay. If a member is considering ivermectin instead of evidence-based care (surgery, chemotherapy, immunotherapy), this is a documented harm. Stage-appropriate curative treatment should not be delayed.
  3. If already using ivermectin off-label: Flag that no anticancer benefit has been demonstrated in humans; ensure it is not replacing standard-of-care treatment; monitor for neurotoxicity signs (tremor, confusion, ataxia) especially with CYP3A4/P-gp inhibitor use.
  4. Monitor clinical trials. The NCT05318469 TNBC trial is worth watching; if it produces a signal, it might eventually justify a CRC trial.

For General Community Members

  • Explain the dose gap clearly: “What kills cancer cells in a lab dish would require doses 20–200 times above what is approved and safe in humans.”
  • Explain the FLT3 claim: “FLT3 is a blood cancer target, not a colon cancer target. The claim is a mistake.”
  • Explain the evidence hierarchy: “Cell lines and mice are not humans. We need clinical trials before we can say a treatment works.”
  • Flag the DOH+ protocol: “This has zero peer-reviewed evidence and is promoted through social media, not oncology conferences or journals.”

Wearable / Biometric Relevance

  • No established wearable signature for ivermectin at approved doses
  • Neurotoxicity at high doses could affect HRV and sleep metrics
  • Not a detection priority for Vitals biometrics

Graph View